John E. Milad

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

Cellnovo is an innovative medical technology company specialising in diabetes. The company develops and markets The Cellnovo System, the world's first mobile, connected, all-in-one diabetes management system that helps make life easier for people with type 1 diabetes. Compact, intuitive and entirely connected, Cellnovo’s micro-pump for insulin delivery communicates wirelessly with a locked-down Android phone, offering the quality and responsiveness that is to be expected from consumer-grade smartphones, while preserving the high-level of security of a medical-grade device. This unique device allows optimal management of diabetes whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. The current version of the system has received CE Mark approval and is reimbursed and available in 10 countries: France, the United Kingdom, The Netherlands, Italy, Spain, Australia, New Zealand, Israel, Greece and Cyprus. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product’s commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to respond to a high level of demand. For more information, visit www.cellnovo.com.

Advanced Cardiac Therapeutics is a medical devices company based out of 1278 Glenneyre St, Laguna Beach, California, United States.

We are pleased to inform you that Boston Scientific has completed its acquisition of Symetis in May 2017. For further information on the ACURATE neo Valve System and jobs at Symetis please visit the Boston Scientific website.

BONESUPPORT AB is a Scandinavian orthobiologics company that develops and markets CERAMENT®, an innovative range of radiopaque injectable osteoconductive and drug-eluting bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery.

Quanta Dialysis Technologies is committed to making dialysis accessible to every patient in every setting with its SC+ hemodialysis system. As a portable device with performance comparable to larger, traditional machines, SC+ is a modular and powerful solution that provides the clinical versatility needed to deliver dialysis care across multiple settings. With a simple-to-use and intuitive user interface, SC+ is designed to be operated by a broad range of users to bring dialysis directly to patients. Disclaimer: The SC+ Haemodialysis system is FDA-cleared for use on patients with acute and/or chronic renal failure when administered by a trained person in an acute or chronic care facility. It is not indicated for home or nocturnal use in the USA. CONTACT US Office / Business Enquiries: UK: 0-178-940-0043 US: 1-978-483-0669 Customer Care: UK: 0-808-164-2640 US: 1-800-590-1393

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

Downing is a responsible investment manager established in London in 1986. We manage £2 billion of assets under a range of investment mandates across our funds, investment trusts and other products. Our key private market investment areas include renewable energy, infrastructure, and residential and operating real estate sectors. In public markets, we have a boutique of specialist fund managers that provide a distinctive suite of investment mandates. Headquartered in London, Downing has operations in the UK, Sweden and Finland.

Otivio AS is a medical device company founded in 2010 and based in Oslo, Norway. In 2021, subsidiaries were established in Denmark and Germany. Otivio’s CE-certified product, FlowOx™, is a novel and non-invasive medical device for hospital and home use. Applications include the treatment of peripheral arterial disease (PAD) related problems such as pain, reduced walking distance and chronic ulcers. The therapeutic value of FlowOx has been proven in numerous clinical and observational studies. Early patient data suggests that FlowOx may also be able to alleviate Multiple Sclerosis (MS) symptoms. The use of FlowOx™ is comfortable and easy: the system generates an intermittent negative pressure (INP) that stimulates the blood circulation in the lower legs and feet, thus improving the blood flow and oxygen supply. The company is looking for partners for commercial development. Contact Otivio at info@otivio.com for more information.

Cellnovo is an innovative medical technology company specialising in diabetes. The company develops and markets The Cellnovo System, the world's first mobile, connected, all-in-one diabetes management system that helps make life easier for people with type 1 diabetes. Compact, intuitive and entirely connected, Cellnovo’s micro-pump for insulin delivery communicates wirelessly with a locked-down Android phone, offering the quality and responsiveness that is to be expected from consumer-grade smartphones, while preserving the high-level of security of a medical-grade device. This unique device allows optimal management of diabetes whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. The current version of the system has received CE Mark approval and is reimbursed and available in 10 countries: France, the United Kingdom, The Netherlands, Italy, Spain, Australia, New Zealand, Israel, Greece and Cyprus. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product’s commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to respond to a high level of demand. For more information, visit www.cellnovo.com.